P. Newsome
Epidemiology · 2009–2023
A researcher in the Science corpus: 11 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Epidemiology — 156 citations into it
- Cell Biology — 8 citations into it
Whom P. Newsome trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from P. Newsome's perspective
Ordered by how strongly the researchers P. Newsome trusts endorse each paper. Same corpus, a different order for every researcher.
- Long‐term follow‐up of patients with NAFLD and elevated liver enzymes (Hepatology)
- Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity (Hepatology)
- Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality (Hepatology)
- Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. (Gastroenterology)
- Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. (Gastroenterology)
- EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease (Obesity Facts)
- Of markets and rights: Discourse in the 2008 and 2013 Global Action Plan for the Prevention and Control of Noncommunicable Diseases
- 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The… (Journal of the American College of Cardiology)
- A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease (American Journal of Gastroenterology)
- Translational control in the endoplasmic reticulum stress response. (Journal of Clinical Investigation)
Their papers
- A multisociety Delphi consensus statement on new fatty liver disease nomenclature (2023) — 2,276 citations
- A multi-society Delphi consensus statement on new fatty liver disease nomenclature. (2023) — 2,621 citations
- Advancing the global public health agenda for NAFLD: a consensus statement (2021) — 631 citations
- A new definition for metabolic associated fatty liver disease: an international expert consensus statement. (2020) — 3,051 citations
- FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study (2020) — 638 citations
- Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. (2020) — 864 citations
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. (2020) — 1,488 citations
- Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. (2019) — 1,205 citations
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. (2019) — 1,024 citations
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. (2016) — 1,869 citations
- Pathogenesis of non-alcoholic fatty liver disease (2009) — 693 citations